JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

ENANTA PHARMACEUTICALS INC

Fechado

SetorSaúde

10.46 -1.69

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.45

Máximo

10.62

Indicadores-chave

By Trading Economics

Rendimento

4.4M

-18M

Vendas

3.4M

18M

Margem de lucro

-99.678

Funcionários

131

EBITDA

5.6M

-15M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+74.41% upside

Dividendos

By Dow Jones

Próximos Ganhos

24 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

182M

321M

Abertura anterior

12.15

Fecho anterior

10.46

Sentimento de Notícias

By Acuity

50%

50%

147 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

ENANTA PHARMACEUTICALS INC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de out. de 2025, 18:41 UTC

Ganhos

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 de out. de 2025, 18:31 UTC

Ganhos

Correction to Procter & Gamble to Focus on Innovation

24 de out. de 2025, 16:25 UTC

Grandes Movimentos do Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 de out. de 2025, 21:07 UTC

Ganhos

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 de out. de 2025, 20:58 UTC

Ganhos

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 de out. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 20:40 UTC

Ganhos

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 de out. de 2025, 20:24 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:23 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:13 UTC

Ganhos

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 20:07 UTC

Conversa de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 de out. de 2025, 19:40 UTC

Conversa de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 de out. de 2025, 19:35 UTC

Conversa de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 de out. de 2025, 19:33 UTC

Ganhos

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 de out. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 de out. de 2025, 18:52 UTC

Ganhos

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:41 UTC

Ganhos

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:03 UTC

Ganhos

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 de out. de 2025, 18:02 UTC

Ganhos

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 de out. de 2025, 18:00 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 de out. de 2025, 16:57 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 de out. de 2025, 16:54 UTC

Conversa de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 de out. de 2025, 16:44 UTC

Conversa de Mercado
Ganhos

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 de out. de 2025, 16:39 UTC

Conversa de Mercado
Ganhos

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 de out. de 2025, 16:33 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:23 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 16:07 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparação entre Pares

Variação de preço

ENANTA PHARMACEUTICALS INC Previsão

Preço-alvo

By TipRanks

74.41% parte superior

Previsão para 12 meses

Média 18.33 USD  74.41%

Máximo 25 USD

Mínimo 9 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para ENANTA PHARMACEUTICALS INC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

5

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.04 / 5.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

147 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat